XKRX
108860
Market cap180mUSD
Oct 07, Last price
8,970.00KRW
1D
-4.47%
1Q
30.38%
Jan 2017
108.36%
IPO
117.02%
Name
Selvas AI Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 1999 and headquartered in Seoul, South Korea, Selvas AI Inc. is an innovator in artificial intelligence (AI) technologies. Its diverse portfolio of AI solutions includes Selvy Note, an AI voice recorder that transcribes conversations from research, consultations, and meetings; Selvy MediVoice, an AI medical voice recognition system facilitating the creation of medical records during clinical processes; and Selvy SpeechEdu, an AI training platform designed for language education, offering text utilization learning, precise sentence pronunciation accuracy, and advanced phoneme-level phonetic training. Further expanding its AI offerings, Selvas AI Inc. provides odiro for AI voice content generation; Selvy Alrimi, an AI announcement system capable of converting text into broadcast voice for automated, scheduled transmission; and Selvy Checkup, an AI solution for predicting the probability of disease occurrence. Beyond AI, the company also offers OnFit, an IoT-based smart program for managing fitness and membership services; Selpub, a cloud-hosted multimedia eBook platform; and DIODICT, a mobile electronic dictionary. The company, originally incorporated as DIOTEK Co., Ltd., underwent a name change to Selvas AI Inc. in September 2016.
Key people
Chief Executive Officer, Director · since 2019
Jae Wu Kang
Assistant Managing Director
Gyeong Seon Kim
Assistant Managing Director
Internal Auditor · since 2011
Dong Yil Kim
Assistant Managing Director · since 2013
Yeong Chan Kim
Assistant Managing Director
Director · since 2011
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||